Skip to content
Clinical Trials – home

GLIQUIDONE: A Treatment for Type 2 Diabetes

0 / 1
trials open to patients / all trials
1+
Countries

In short

This article delves into clinical trials investigating the use of Gliquidone, also known by its brand name Glurenorm®, in treating Type 2 Diabetes. We'll explore how this medication compares to other treatments in terms of effectiveness and safety, particularly in Chinese patients who haven't received previous diabetes treatment. The information provided will help patients better understand the ongoing research and potential benefits of Gliquidone in managing Type 2 Diabetes.

At a glance

Study Title
Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes
Location
Asia (focusing on Chinese subjects)
Medications Studied
Repaglinide, Glurenorm® (Gliquidone), Glucobay®
Study Population
Treatment-naive Chinese subjects with Type 2 Diabetes
Treatment Duration
3 months
Primary Measurements
Fasting blood glucose, Hypoglycemia episodes
Study Aim
Compare efficacy and safety of the three medications as mono-therapy

Introduction to GLIQUIDONE

GLIQUIDONE, also known by its brand name Glurenorm®, is a medication used in the treatment of type 2 diabetes mellitus. This drug is part of a clinical trial comparing its effectiveness and safety with other diabetes medications in Chinese patients. Type 2 diabetes is a chronic condition that affects how your body processes glucose (sugar), which is an important source of energy for your cells.

What is GLIQUIDONE?

GLIQUIDONE belongs to a class of medications called sulfonylureas. These drugs are used to help control blood sugar levels in people with type 2 diabetes. In the clinical trial, GLIQUIDONE (Glurenorm®) is being studied alongside other diabetes medications such as repaglinide and Glucobay®. It's important to note that GLIQUIDONE is specifically designed for patients with type 2 diabetes, not type 1 diabetes or other forms of the condition.

How GLIQUIDONE Works

GLIQUIDONE works by stimulating the pancreas to produce more insulin. Insulin is a hormone that helps your body's cells absorb glucose from the bloodstream. By increasing insulin production, GLIQUIDONE helps lower blood sugar levels in people with type 2 diabetes. This mechanism of action is similar to other sulfonylurea drugs used in diabetes treatment.

Efficacy and Safety

The clinical trial mentioned in the source is designed to evaluate the efficacy and safety of GLIQUIDONE (Glurenorm®) compared to other diabetes medications. The study focuses on Chinese subjects with type 2 diabetes who have not previously received treatment for their condition. The primary goal of the study is to assess how well these medications work after three months of treatment.

Some of the key aspects being evaluated include:

  • Fasting blood glucose: This measures the amount of glucose in your blood after an overnight fast. It's an important indicator of how well your diabetes is being controlled.
  • Hypoglycemia episodes: These are instances when your blood sugar drops too low, which can be a side effect of diabetes medications. The study is monitoring how often these episodes occur with different treatments.

Comparison with Other Diabetes Medications

The clinical trial is comparing GLIQUIDONE (Glurenorm®) with two other diabetes medications:

  1. Repaglinide: This is another type of medication that stimulates insulin release from the pancreas, but it belongs to a different drug class called meglitinides.
  2. Glucobay®: This is the brand name for acarbose, which works differently from GLIQUIDONE. It slows down the digestion of carbohydrates in your intestines, which helps control blood sugar levels after meals.

By comparing these different medications, researchers hope to determine which treatment might be most effective and safe for Chinese patients with type 2 diabetes.

Potential Side Effects

While the clinical trial data doesn't provide specific information about side effects, it's important to be aware that all medications can have potential side effects. For sulfonylureas like GLIQUIDONE, one of the most significant potential side effects is hypoglycemia (low blood sugar), which is being specifically monitored in the study. Symptoms of hypoglycemia can include shakiness, dizziness, sweating, and confusion. It's crucial to discuss potential side effects with your healthcare provider and learn how to recognize and manage them.

Questions people often ask

Conditions where Gliquidone is being studied

Each condition opens its own overview and trial list

Trials with Gliquidone

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).